Form 4: Oragenics Director Pope Awarded 125,000 Stock Options

Oragenics Inc. Director Charles L. Pope received an award of 125,000 stock options with an exercise price of $0.93, vesting immediately, under the company's equity incentive plan.

Summary

• Charles L. Pope, a Director of Oragenics Inc. (OGEN), was awarded 125,000 non-employee director options.
• The options have an exercise price of $0.93 per share.
• The award was made on December 11, 2025.
• These options vest immediately upon grant.
• The options expire on December 11, 2035.
• The award is part of the Company's 2021 Equity Incentive Plan, as amended, and its non-employee director compensation program.

Sentiment

Score: 6

Explanation: The filing reports a standard compensation event for a director, which is generally neutral but can be seen as slightly positive for aligning director interests with shareholders. There are no significant positive or negative financial implications for the company beyond potential future dilution.

Positives

• The award of 125,000 stock options to Director Charles L. Pope aligns his interests with those of shareholders.
• Immediate vesting of the options provides immediate equity exposure and incentive.
• The options were granted under an established and approved 2021 Equity Incentive Plan.

Negatives

• Potential for future dilution if the options are exercised, adding 125,000 shares to the outstanding common stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction, as it is solely an insider transaction report.

Industry Context

The award of stock options to non-employee directors is a common practice in the biotechnology and pharmaceutical industry, including for companies like Oragenics Inc., to attract and retain qualified board members and align their long-term interests with shareholder value creation. The exercise price being the closing price on the grant date is also standard practice.

Corporate Governance

Related Party Transactions

• The award of stock options to Charles L. Pope, a Director of Oragenics Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also improved alignment of director's interests with shareholder value.

Next Steps

• The director may choose to exercise these options at any point before their expiration date, subject to market conditions and personal financial planning.
• Future Form 4 filings would report any exercise or sale of these options or underlying shares.

Key Dates

Keywords

Oragenics Inc., OGEN, Charles L. Pope, Director, Stock Options, Equity Incentive Plan, Insider Transaction, Form 4, Compensation